Hepatitis C Virus

Schering-Plough Announces Rebetol Approval In Japan

Published in Hepatitis Weekly, December 17th, 2001

Schering-Plough K.K., Schering-Plough Corp.'s subsidiary in Japan, has received marketing approval from the Ministry of Health, Labor and Welfare (MHLW) for Rebetol (ribavirin) capsules for use only in combination with interferon alfa-2b (recombinant) injection (Intron A) for the treatment of chronic hepatitis C.

Rebetol and Intron A constitute the first combination therapy approved in Japan for treating chronic hepatitis C. Rebetol will be launched in Japan upon receiving pricing approval.

Hepatitis C is estimated to affect 2 million people in Japan, according to MHLW. It is the leading cause in Japan of chronic liver disease, cirrhosis and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry